Blindness News and Research

RSS

Raltegravir could be valid target against all Herpesviridae

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus.

23 Sep 2010

Six3 gene safeguards future retina

New research led by St. Jude Children's Research Hospital investigators adds to evidence that the Six3 gene functions like a doorman in the developing brain and visual system, safeguarding the future retina by keeping the region where the eye is forming free of a signaling protein capable of disrupting the process.

21 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

AMDAI launches 'Don't Surrender to AMD' public awareness campaign

Age-related Macular Degeneration (AMD), which affects more than 10 million older Americans, continues to be the leading cause of vision loss in the United States. The global cost of the disease according to a recent report by AMD Alliance International (AMDAI) is estimated at $343 billion, underscoring the need for swift actions to raise awareness of prevention and treatment options.

18 Sep 2010

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program) to fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Alpha 1 Antitrypsin Deficiency (AAT), a genetic disease known to result in serious lung and/or liver disease.

17 Sep 2010

Artificial pancreas for diabetics

In another few years diabetics may be treated using an artificial pancreas developed by Professor Joan Taylor professor of Pharmaceutics at De Montfort University (DMU), Leicester. This could mean freedom from daily insulin injections she said.

16 Sep 2010

BioResonator signs new orders for glaucoma diagnostic product distribution

BioResonator signs new orders with several new distributors. As of one month, the company has the official CE approval required to sell their products throughout the European Union.

16 Sep 2010

Danny Davis to discuss diabetes, obesity rates in U.S. at UIC Midwest Conference

U.S. Rep. Danny Davis (D-Chicago) will give opening remarks when the Institute of Medicine of the National Academies convenes a regional meeting Sept. 21 at the University of Illinois at Chicago to discuss the rapidly rising rates of diabetes and obesity in the U.S.

15 Sep 2010

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program). The grant will fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis (LCA), a genetic retinal disease known to cause blindness at an early age.

14 Sep 2010

Myopia and Glaucoma genes identified

In global studies of more than 40,000 people from countries around the world, including Australia, researchers have found the genes responsible for two of the most common eye disorders - short-sightedness or myopia and glaucoma. The scientists believe this could open new diagnostic and management options.

13 Sep 2010

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

13 Sep 2010

JDRF selects Convio's Common Ground CRM for primary constituent relationship management

Convio, Inc. announced today that Juvenile Diabetes Research Foundation (JDRF) has selected Convio as their standard for constituent relationship management (CRM), online marketing and fundraising, and special events for JDRF's national headquarters and all chapters. JDRF will use Convio's integrated, on-demand marketing, fundraising and advocacy suite to power and support their efforts to engage constituents and raise money.

13 Sep 2010

Scientists discover gene associated with myopia

Myopia (nearsightedness) is the most common eye disorder in the world and becoming more common, yet little is known about its genetic underpinnings.Scientists at Duke University Medical Center, in conjunction with several other groups, have uncovered a gene associated with myopia in Caucasian people from several different regions, including Dutch, British and Australian subjects.

13 Sep 2010

Scientists discover SNP association with primary open-angle glaucoma risk

Scientists at deCODE genetics and academic colleagues from Iceland, China, Sweden, the UK and Australia today report the discovery of the most important single-letter variation (SNP) in the sequence of the human genome yet associated with risk of primary open-angle glaucoma. This is the most common form of glaucoma and a major cause of blindness worldwide.

13 Sep 2010

Clinica of Virginia offers medical services to Medicare and Medicaid patients for $1.00

In an effort to promote wellness and help those who are struggling to make ends meet, Clinica of Virginia, LLC. is providing quality medical services to Medicare and Medicaid patients for only $1.00. The national economic downturn, combined with national bureaucracy, has created a shortage of physicians and clinics who accept Medicare and Medicaid. Chronic, multiple medical conditions plague those Americans who can financially afford it the least, and physicians' offices who accept Medicare or Medicaid are now far and few between. Clinica accepts both.

10 Sep 2010

Researchers investigate familial prosopagnosia to recognize faces

In our dynamic 3D world, we can encounter a familiar face from any angle and still recognize that face with ease, even if the person has, for example, changed his hair style. This is because our brain has used the 2D snapshots perceived by our eyes (like a camera) to build and store a 3D mental representation of the face, which is resilient to such changes.

9 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

6 Sep 2010

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept. 11 on "Twenty-first Century Bioscience: In Silico Methods and High-Throughput Screening," which will feature a variety of cutting-edge advances in the field developed by researchers in Western New York and throughout the US.

3 Sep 2010

Alcon to launch AcrySof IQ ReSTOR Multifocal Toric intraocular lens outside US during 2010 ESCRS meeting

Alcon, Inc., the world's leader in eye care and cataract surgery, announced its launch of the AcrySof® IQ ReSTOR® Multifocal Toric intraocular lens (IOL) outside the United States during the 2010 European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting in Paris, France. This new lens is built on Alcon's industry leading AcrySof® platform and is designed to provide cataract patients that have astigmatism a surgical option that delivers quality vision at all distances with increased spectacle independence.

3 Sep 2010

Blindness News and Research

Raltegravir could be valid target against all Herpesviridae

Six3 gene safeguards future retina

Lisofylline drug effective for Type 2 diabetes

AMDAI launches 'Don't Surrender to AMD' public awareness campaign

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

Artificial pancreas for diabetics

BioResonator signs new orders for glaucoma diagnostic product distribution

Danny Davis to discuss diabetes, obesity rates in U.S. at UIC Midwest Conference

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Myopia and Glaucoma genes identified

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

JDRF selects Convio's Common Ground CRM for primary constituent relationship management

Scientists discover gene associated with myopia

Scientists discover SNP association with primary open-angle glaucoma risk

Clinica of Virginia offers medical services to Medicare and Medicaid patients for $1.00

Researchers investigate familial prosopagnosia to recognize faces

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

Alcon to launch AcrySof IQ ReSTOR Multifocal Toric intraocular lens outside US during 2010 ESCRS meeting

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News